The US Food and Drug Administration approvals of Day One Biopharmaceuticals, LLC’s Ojemda (tovorafenib) and ImmunityBio Inc.’s Anktiva (nogapendekin alfa inbakicept-pmln) last week provided a boost to what has been an anemic 2024 for novel cancer therapies.
Keeping Track: Two Breakthrough Oncologics, Another Antibiotic Clear US FDA Along With Pfizer’s Hemophilia B Gene Therapy
The US FDA approved Day One’s pediatric brain cancer drug Ojemda, ImmunityBio’s bladder cancer immunotherapy Anktiva, an uncomplicated UTI claim for Utility Therapeutics’ Pivya, which has a long history in Europe, and Pfizer’s hemophilia B gene therapy Beqvez.
